Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · Real-Time Price · USD
1.380
-0.010 (-0.72%)
Feb 21, 2025, 4:00 PM EST - Market closed
Achilles Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Buy
Price Target
$4.00
Upside
+189.86%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +44.93% | Apr 5, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $6 | Strong Buy | Maintains | $11 → $6 | +334.78% | Apr 5, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $0.5 | Strong Buy → Sell | Downgrades | $7 → $0.5 | -63.77% | Dec 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +697.10% | Aug 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +697.10% | May 11, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +1,131.88% | Dec 7, 2022 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +479.71% | Dec 7, 2022 |
| JP Morgan | JP Morgan | Sell Initiates $11 | Sell | Initiates | $11 | +697.10% | Apr 26, 2021 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +1,856.52% | Apr 26, 2021 |
| Piper Sandler | Piper Sandler | Buy Initiates $25 | Buy | Initiates | $25 | +1,711.59% | Apr 26, 2021 |
| Oppenheimer | Oppenheimer | Buy Initiates $23 | Buy | Initiates | $23 | +1,566.67% | Apr 26, 2021 |